olivLaw · US equity research
Alignment Healthcare, Inc. ALHC
Hospital & Medical Service Plans · SIC 6324 · Vertical: Hospital & Medical Service Plans (SIC 6324)
Alignment Healthcare is a consumer-centric, clinically focused platform that runs Medicare Advantage plans for seniors, receiving a fixed monthly payment per member and taking responsibility for care and cost outcomes. Growth in revenue and membership continued into 2026, but results depend on maintaining quality and CMS ratings in a regulated, competitive sector. Revenue reached 3948.7 million USD in 2025 and membership reached 294100 by June 2026.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Alignment Healthcare, Inc. (ALHC) stock was 8.14 USD (+10.15% on the day), with market capitalisation 1.7 bn USD, P/E 71.3 on diluted EPS of 0.11 USD over the last 12 months, beta 0.22, 52-week range 7.00–24.56 USD. Latest reported quarter (Q3 2026): revenue of 1.4 bn USD (+36.7% YoY), net income of -8.1 m USD (−315.9% YoY), diluted EPS -0.04 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 47.0
- neutral
- Bollinger (20, 2)
- 7.20 – 8.91
- in the upper half of the band · %B 0.55 · band width 21.3%
- SMA 50 / 200
- 9.52 / 16.59
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.48 / -0.56
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −4.2% | −1.1% | −3.1 pp | — |
| 3 months | −40.5% | −0.5% | −40.0 pp | — |
| 6 months | −55.1% | +4.4% | −59.5 pp | — |
| Year to date | −58.8% | +12.3% | −71.1 pp | — |
| 1 year | −52.4% | +13.5% | −65.9 pp | +52.7% |
| 3 years | +35.2% | +76.4% | −41.2 pp | +3.2% |
| 5 years | −63.2% | +63.7% | −126.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 701.2 m | 926.9 m | 1.0 bn | 993.7 m | 1.0 bn | 1.2 bn | 1.3 bn | 1.4 bn |
| SG&A | 102.1 m | 103.8 m | 103.8 m | 110.0 m | 125.8 m | 121.1 m | 131.0 m | 136.4 m |
| Operating income | -22.5 m | -5.4 m | 22.7 m | 7.7 m | -10.3 m | 15.5 m | 42.1 m | -3.8 m |
| Depreciation & amortisation | 6.8 m | 7.6 m | 7.0 m | 8.0 m | 7.8 m | 7.8 m | 7.9 m | 8.1 m |
| Interest expense | 5.5 m | 4.0 m | 4.0 m | 4.0 m | 3.9 m | 4.1 m | 4.3 m | 4.3 m |
| Pre-tax income | -31.1 m | -9.3 m | 18.9 m | 3.7 m | -14.2 m | 11.4 m | 37.8 m | -8.1 m |
| Income tax | 7.0 k | 21.0 k | 3.2 m | 2.0 k | -3.2 m | 25.0 k | 1.3 m | -22.0 k |
| Net income | -31.1 m | -9.1 m | 15.7 m | 3.7 m | -11.0 m | 11.4 m | 36.6 m | -8.1 m |
| Diluted EPS | -0.16 ≈ | -0.05 | 0.07 | 0.02 | -0.07 ≈ | 0.05 | 0.17 | -0.04 |
| Operating cash flow | -8.7 m | 16.6 m | 29.1 m ≈ | 144.6 m ≈ | -50.4 m | 128.7 m | -17.3 m ≈ | 47.0 m ≈ |
| Capex | 9.3 m | 8.3 m | 8.0 m ≈ | 5.5 m ≈ | 5.0 m | 7.4 m | 10.1 m ≈ | 8.4 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 3-quarter history (min 71.5, median 136.7, max 237.7; quarters with earnings only).
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 757.0 m | 959.2 m | 1.2 bn | 1.4 bn | 1.8 bn | 2.7 bn | 3.9 bn |
| Revenue YoY | unavailable | +26.7% | +21.7% | +22.8% | +27.2% | +48.3% | +46.1% |
| Net income | -44.7 m | -22.9 m | -195.3 m | -149.5 m | -148.0 m | -128.0 m | -724.0 k |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -0.15 | -1.14 | -0.83 | -0.79 | -0.67 | 0.00 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -5.9% | -2.4% | -16.7% | -10.4% | -8.1% | -4.7% | -0.0% |
| Free cash flow | unavailable | unavailable | unavailable | -69.2 m | -95.2 m | -6.6 m | 113.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 575.8 m USD
- Financial debt
- 323.2 m USD
- Net debt
- -252.6 m USD
- Equity
- 179.3 m USD
- Total assets
- 1.1 bn USD
- Debt / equity
- 1.80x
- Current ratio
- 1.71x
- ROE
- -0.5%
- ROA
- -0.1%
- FCF margin
- 2.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Pre-tax income | -22.9 m | -195.3 m | -149.3 m | -148.2 m | -128.1 m | -958.0 k | SEC (XBRL)· 27 Feb 2026verified |
| Net income | -22.9 m | -195.3 m | -149.5 m | -148.0 m | -128.0 m | -724.0 k | SEC (XBRL)· 27 Feb 2026verified |
| Diluted EPS | -0.15 | -1.14 | -0.83 | -0.79 | -0.67 | 0.00 | SEC (XBRL)· 27 Feb 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 207.3 m | 466.6 m | 409.5 m | 202.9 m | 432.9 m | 575.8 m | SEC (XBRL)· 27 Feb 2026verified |
| Total assets | 338.5 m | 630.9 m | 633.9 m | 591.9 m | 782.1 m | 1.1 bn | SEC (XBRL)· 27 Feb 2026verified |
| Short-term debt | 0 | 0 | 0 | 0 | 0 | 0 | SEC (XBRL)· 27 Feb 2026verified |
| Long-term debt | 144.2 m | 150.6 m | 160.9 m | 161.8 m | 321.4 m | 323.2 m | SEC (XBRL)· 27 Feb 2026verified |
| Total liabilities | 307.9 m | 324.8 m | 394.6 m | 433.8 m | 681.1 m | 886.5 m | SEC (XBRL)· 27 Feb 2026verified |
| Equity | 30.6 m | 306.1 m | 239.3 m | 158.1 m | 101.0 m | 179.3 m | SEC (XBRL)· 27 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Market and valuation
Insurance
32 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.7 bn USD
Key indicators
Coverage and freshness
Score by group
62% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 1.41 – 4.22 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- Residual income1.41 – 1.48 (Mid 1.45)
- Justified P/B1.81 – 2.44 (Mid 2.08)
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
- Peers: P/E2.25 – 2.95 (Mid 2.77)6 companies used · median multiple 24.3x · quartiles 19.7x – 25.8xCI, CNC, ELV, HUM, OSCR, UNH
- Peers: P/B2.64 – 4.22 (Mid 3.57)7 companies used · median multiple 2.7x · quartiles 2.0x – 3.2xCI, CNC, ELV, HUM, MOH, TRUP, UNH
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROE · Quality | 13.2% | 63 (vs peers) | 29% |
| Loss ratio · Quality | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 40.2% | 100 (on a fixed band) | 13% |
| ROA · Balance sheet | 2.4% | 76 (on a fixed band) | 13% |
| P/B · Valuation | 6.1x | 0 (vs peers) | 23% |
| P/E (TTM) · Valuation | 71.3x | 14 (vs peers) | 23% |
| Dividend yield · Returns | unavailable | unavailable | — |
| Payout ratio (EPS) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet76/100 · 1/1 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial63/100 · 1/2 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation7/100 · 2/2 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ALIGNMENT HEALTHCARE, INC. (ALHC). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: YoY growth 46.1%; net margin 0.6%; ROE 13.2%.
The estimated value range is 2.03–2.69 USD per share (median of 4 methods, agreement: medium); assumptions are illustrative. Against the central value of 2.43 USD, the price of 8.14 USD leaves a potential of -70.2% (value / price − 1) and a margin of safety of -235.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 40.2%
- ROA: 2.4%
What contradicts it
- P/B: 6.1x
- P/E (TTM): 71.3x
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): Loss ratio, EPS CAGR 3Y, Dividend yield, Payout ratio (EPS).
Versus the vertical median
Hospital & Medical Service Plans (SIC 6324) · same industry (4-digit SIC) · compared with 9 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| UNHUnitedHealth Group Incorporated | 366.8 bn | 23.4 | 15.4% | 3.5% | +11.8% | +24% / −26% |
| ELVElevance Health, Inc. | 93.8 bn | 18.5 | 11.6% | 2.5% | +12.5% | +28% / −9% |
| CIThe Cigna Group | 80.7 bn | 13.2 | 15.0% | 2.2% | +11.2% | +10% / +16% |
| HUMHumana Inc | 50.1 bn | 44.5 | 6.2% | 0.8% | +10.1% | +70% / −14% |
| CNCCentene Corporation | 37.6 bn | 26.0 | 6.8% | 0.7% | +19.4% | +93% / +3% |
| MOHMolina Healthcare, Inc. | 11.8 bn | — | -1.2% | -0.1% | +11.7% | +53% / −38% |
| ALHCAlignment Healthcare, Inc. | 1.7 bn | 71.3 | 13.2% | 0.6% | +46.1% | −52% / +35% |
| TRUPTrupanion, Inc. | 1.5 bn | 74.8 | — | — | +11.9% | −5% / +31% |
| OSCROscar Health, Inc. | — | 25.2 | 34.3% | 3.6% | +27.5% | +96% / +314% |
| CLOVClover Health Investments, Corp. | — | — | -5.1% | -0.7% | +40.3% | +88% / +409% |
1- and 3-year price returns: for ALHC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 6.44 Total return -21% · Per year -21% | 11.34 Total return 39% · Per year 39% | 17.00 Total return 109% · Per year 109% |
| 3 years | 7.64 Total return -6% · Per year -2% | 14.99 Total return 84% · Per year 23% | 24.48 Total return 201% · Per year 44% |
| 5 years | 9.06 Total return 11% · Per year 2% | 19.83 Total return 144% · Per year 19% | 35.26 Total return 333% · Per year 34% |
- Exit P/E± 3.75
- Net margin± 2.62
- Annual revenue growth± 1.96
- Annual dilution± 0.22
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 30 Jul 2026; since then the company filed 8-K (29 Oct 2026 · results), 10-Q (29 Oct 2026).
In brief
Alignment Healthcare is a consumer-centric, clinically focused platform that runs Medicare Advantage plans for seniors, receiving a fixed monthly payment per member and taking responsibility for care and cost outcomes. Growth in revenue and membership continued into 2026, but results depend on maintaining quality and CMS ratings in a regulated, competitive sector. Revenue reached 3948.7 million USD in 2025 and membership reached 294100 by June 2026 12.
SWOT
Strengths
- Integrated care model with an in-house clinical team and the AVA data platform, which support medical results and membership growth.
- Consistent growth in revenue and membership, with operating results above earlier expectations in the latest reported quarter.
- All members are in plans with high ratings, which supports retention and broker attraction.
Weaknesses
- A history of net losses and a large accumulated deficit limit financial flexibility.
- Near-total dependence on CMS contracts and a limited number of states makes the company vulnerable to policy changes.
- Clinical staffing and technology costs are high, and margins could be squeezed if medical costs rise.
Opportunities
- A small market share in existing markets leaves room for growth, and expansion into new states could add members.
- Acquisitions of care groups or Medicare Advantage plans could accelerate expansion if executed well.
- Wider use of AVA and AI tools could lower costs and improve operating efficiency.
Threats
- Cuts to federal Medicare Advantage funding could directly reduce revenue and margins.
- Loss of major physician group or hospital contracts could affect members' access to care.
- Cybersecurity incidents or errors in AI models could expose the company to liability and penalties.
Risks
- Dependence on CMS contractshigh
Almost all revenue comes from CMS contracts, and changes in payments, audits or suspension from the program could severely affect the company.
- Quality ratingshigh
A decline in CMS ratings could reduce financial incentives and revenue, especially in the years after the rating year.
- Medical expense estimatesmedium
Inaccurate estimates of reported or unreported medical costs could distort results and quarterly margins.
- Cybersecurity and AImedium
Attacks on member data or errors in machine learning systems could create operational and legal losses.
- Geographic concentrationlow
Plans are concentrated in a limited number of states, so a regional event or a local regulatory change could have a significant effect.
Investment thesis
What would need to be true (bull case)
- If membership and revenue growth continue and margins improve, the company could show that its managed-care model delivers durable results.
- A still-small market share and planned expansion into new states could support long-term growth.
- The 2026 guidance, raised after the second-quarter results, suggests management confidence in reaching annual targets.
What would break the thesis
- Dependence on federal funding and CMS ratings could leave revenue exposed to policy changes or a fall in perceived quality.
- The loss history and accumulated deficit could limit the company's ability to fund growth without additional capital.
- Medical costs of the chronic population could rise faster than payments received, which could compress margins.
What to watch
- Third-quarter results and whether revenue and adjusted profit land within guidanceQ3 2026
- Trend in the medical benefits ratio and adjusted gross profit marginQ3 2026
- CMS ratings for the following year, which will influence revenue2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 30 Jul 2026; since then the company filed 8-K (29 Oct 2026 · results), 10-Q (29 Oct 2026).
The business
Plans are offered in 45 markets across California, North Carolina, Nevada, Arizona and Texas, where about 8.5 million Medicare-eligible seniors live in the 2026 plan year 2. Members are sorted into four categories (healthy, healthy utilizer, pre-chronic and chronic), and Care Anywhere focuses on high-risk patients with home visits and virtual consultations at no cost to members 1. Revenue comes almost entirely from CMS contracts tied to Medicare Advantage plans 1.
The company aims to become the most trusted senior healthcare brand in the country and to bring its model to millions of people, relying on a hybrid virtual and in-home approach rather than capital-intensive physical facilities 1.
Segments
Medicare Advantage plans (HMO and PPO)
This segment accounts for almost all revenue and covers members enrolled in HMO and PPO contracts. Revenue is linked to membership counts and plan quality as measured by CMS star ratings 12.
Care Anywhere clinical care
Employed physicians, clinicians and social workers deliver in-home and telephonic care to chronic patients, aiming to reduce hospitalizations and readmissions. This activity carries its own cost but supports the plans' medical results 1.
AVA technology platform
AVA is the proprietary platform combining longitudinal data, predictive models and machine learning for internal teams, provider partners and brokers 1. It supports operations but also brings security and regulatory risks.
Market context
Trends
- Growing senior populationtailwind
The Medicare-eligible population keeps rising, and the number of seniors in the company's markets moved from 8.4 million in 2025 to 8.5 million in 2026 12. This could support enrollment if the company holds its position in these markets.
- Medical cost pressureheadwind
Chronically ill seniors generate most of the spending, and costs can rise as members age. If the medical benefits ratio deteriorates, margins could be affected 12.
- CMS quality ratingsmixed
Plans with high ratings receive financial incentives, and the current portfolio is entirely in plans rated at least 4 stars 2. Keeping this level depends on member satisfaction and care quality, and a drop in ratings could reduce revenue.
- Regulation and federal fundingheadwind
The company depends on CMS contracts and Medicare Advantage program rules. Funding cuts, legislative changes or government audits could directly affect revenue and the business model 13.
Competitive position
Alignment competes with other Medicare Advantage plans, mainly large, well-established insurers in the markets where it operates, some with greater resources than its own. Competition for provider contracts and medical staff could intensify through sector consolidation 1.
The company's edge lies in its managed-care model with employed clinical staff and a data platform, rather than the prior-authorization approach typical of many traditional insurers 1. This edge could be copied by competitors with similar resources.
- HumanaHUM
Large company with Medicare Advantage plans, cited in the senior-market competitive landscape.
- UnitedHealth GroupUNH
Large insurer offering Medicare Advantage plans and competing for members and provider contracts.
- CenteneCNC
Provider of Medicare Advantage and Medicaid plans, competing for enrollment and local provider contracts.
- Local providers and independent physician associations (IPAs)
Provider groups with which the company negotiates contracts; losing or renegotiating them could affect results.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Cyprus: From ties with Russia to a strategic alignment with the USDW (Deutsche Welle) — Europe · 03 Nov 2026 · EN
- OPINION - Did alignment with Israel influence Serbia’s elections?Anadolu Agency (TR, EN) · 02 Nov 2026 · EN
- Making alignment the agent's problemLessWrong · 29 Oct 2026 · EN
- Import AI 478: Math for alignment; ProgramBench; and Mirendil shows what RSI meansImport AI · 26 Oct 2026 · EN
- Control monitors need alignment assessments tooLessWrong · 25 Oct 2026 · EN
- An alignment assessment of the UK AISI cybertesting incidentHacker News · 23 Oct 2026 · EN
- The Alignment Journal: Our Approach and Related ProjectsLessWrong · 22 Oct 2026 · EN
- The Alignment Problem: Computer Science Meets Analytic PhilosophyLessWrong · 18 Oct 2026 · EN
- The Alignment Problem: Computer Science Meets Analytic PhilosophyAI Alignment Forum · 18 Oct 2026 · EN
- [AINews] Agents disprove Polysemanticity; greatly improve Interpretability & AlignmentLatent Space Newsletter · 16 Oct 2026 · EN
- [AINews] Agents disprove Polysemanticity; greatly improve Interpretability & AlignmentLatent Space Newsletter · 16 Oct 2026 · EN
- Preface to the Computational Agent Theory and ASI Alignment SequenceLessWrong · 15 Oct 2026 · EN
- Preface to the Computational Agent Theory and ASI Alignment SequenceAI Alignment Forum · 15 Oct 2026 · EN
- Chile, Bolivia Seek Diplomatic Reset in New Right-Wing AlignmentBloomberg Markets · 15 Oct 2026 · EN
- Labs’ current alignment plans seem terribleLessWrong · 12 Oct 2026 · EN
- An Alignment Forum for AIs? (or: Verification in the Age of Slop)LessWrong · 10 Oct 2026 · EN
- Podcast: The Minimum Viable Manager: Building Trust, Feedback, and AlignmentInfoQ · 09 Oct 2026 · EN
- Crystal alignment explains why magnesium alloy plates resist ballistic impacts better in one directionPhys.org · 06 Oct 2026 · EN
- “Alignment Engineering” vs. “Misalignment Science”LessWrong · 05 Oct 2026 · EN
- Multi-Alignment Pays, but Washington and Beijing Set the PriceModern Diplomacy · 03 Oct 2026 · EN
SEC filings
- Quarterly report29 Oct 2026
- Current report29 Oct 2026Results of operations · Financial statements and exhibits
- Current report08 Oct 2026Regulation FD disclosure
- Quarterly report30 Jul 2026
- Current report30 Jul 2026Results of operations · Financial statements and exhibits
- Current report09 Jun 2026Shareholder vote
- Current report12 May 2026Amendments to articles or bylaws · Regulation FD disclosure
- Quarterly report30 Apr 2026
- Current report30 Apr 2026Results of operations · Financial statements and exhibits
- Proxy statement24 Apr 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Alignment Healthcare, Inc. · 27 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Alignment Healthcare, Inc. · 30 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Alignment Healthcare, Inc. · 30 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.